Treatment Approaches for Prolactinomas in Postmenopausal Women: A Retrospective Analysis from a Single Center - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Treatment Approaches for Prolactinomas in Postmenopausal Women: A Retrospective Analysis from a Single Center

  • By

  • Xiaoxue Chen

  • Yixin Lu

  • Jiayu Liu

  • Xiaoan Ke

  • Hui Miao

  • Lian Duan

  • Fengying Gong

  • Hongbo Yang

  • Hui Pan

  • Linjie Wang

  • Huijuan Zhu

  • December 29, 2025

Share

  • 1

    Prolactinomas are the most common pituitary adenomas, primarily affecting women aged 25–44, with a changing prevalence in postmenopausal women.

  • 2

    Dopamine agonists like cabergoline and bromocriptine are the primary treatments for prolactinomas, requiring long-term monitoring for recurrence.

  • 3

    Menopause may positively influence the disease course, with some patients achieving remission after dopamine agonist withdrawal.

  • 4

    This study analyzed 104 postmenopausal women with prolactinomas to evaluate treatment responses and outcomes related to dopamine agonist therapy.

  • 5

    The findings aim to inform standardized management strategies for prolactinoma in postmenopausal women, addressing a significant research gap.

Original Source(s)

Treatment Approaches for Prolactinomas in Postmenopausal Women: A Retrospective Analysis from a Single Center

  • by Xiaoxue Chen, Yixin Lu, Jiayu Liu, Xiaoan Ke, Hui Miao, Lian Duan, Fengying Gong, Hongbo Yang, Hui Pan, Linjie Wang, Huijuan Zhu

  • December 29, 2025

Related Content

Exploring the Shared Genetic Basis of Age at Menopause and Osteoarthritis

Divergence in Menopause Symptom Narratives Between Online and Clinical Settings

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.